ScholarIQanswers from OpenAlex
Hemophilia Treatment and Research
TopicLeading institutions, researchers & key papers
Hemophilia Treatment and Research is a topic indexed in ScholarIQ from OpenAlex.
What is known about Hemophilia Treatment and Research?
ScholarIQrecord summary
This cluster of papers focuses on the management and treatment of hemophilia, including prophylaxis, inhibitors, gene therapy, and the impact on joint health. It covers a wide range of topics such as recombinant factor VIII, factor IX, and the safety and efficacy of various treatment strategies.
How many works does Hemophilia Treatment and Research have?
ScholarIQindexed works
Hemophilia Treatment and Research has 86 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Hemophilia Treatment and Research?
ScholarIQopenalex
The OpenAlex for Hemophilia Treatment and Research is on the source record.
What are the most-cited papers on Hemophilia Treatment and Research?
ScholarIQmost cited works
Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia
Marilyn J. Manco‐Johnson, Thomas C. Abshire, Amy D. Shapiro, Brenda Riske, Michele R. Hacker, Ray F. Kilcoyne, J. David Ingram, M L Manco-Johnson, Sharon Funk, Linda Jacobson, Leonard A. Valentino, W. Keith Hoots, George R. Buchanan, Donna DiMichele, Michael Recht, Deborah Brown, Cindy Leissinger, Shirley Bleak, Alan R. Cohen, Prasad Mathew, Alison Matsunaga, Desiree Medeiros, Diane J. Nugent, Gregory A. Thomas, Alexis A. Thompson, Kevin McRedmond, J. Michael Soucie, Harlan Austin, Bruce L. Evatt
Safety of Recombinant Activated Factor VII in Randomized Clinical Trials
Marcel Levi, Jerrold H. Levy, Henning Friis Andersen, David Truloff
Nonviral Transfer of the Gene Encoding Coagulation Factor VIII in Patients with Severe Hemophilia A
David A. Roth, Nicholas E. Tawa, Joanne O’Brien, Douglas A. Treco, Richard F. Selden
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
Steven W. Pipe, Frank W.G. Leebeek, Michael Recht, Nigel S. Key, Giancarlo Castaman, Wolfgang Miesbach, Susan Lattimore, Kathelijne Peerlinck, Paul van der Valk, Michiel Coppens, Peter Kampmann, Karina Meijer, Niamh O’Connell, John Pasi, Daniel P. Hart, Rashid Kazmi, Jan Astermark, Cédric Hermans, Robert Klamroth, Richard S. Lemons, Nathan Visweshwar, Annette von Drygalski, Guy Young, Shelley E. Crary, Miguel A. Escobar, Esteban Gomez, Rebecca Kruse‐Jarres, Doris Quon, Emily Symington, Michael Wang, Allison P. Wheeler, Robert Gut, Ying P. Liu, Ricardo E. Dolmetsch, David L. Cooper, Yanyan Li, Brahm Goldstein, Paul E. Monahan
Results of the CONTROL Trial: Efficacy and Safety of Recombinant Activated Factor VII in the Management of Refractory Traumatic Hemorrhage
Carl J. Hauser, Kenneth D Boffard, Richard P. Dutton, Gordon R. Bernard, Martin A. Croce, John B. Holcomb, Ari Leppäniemi, Michael Parr, Jean‐Louis Vincent, Bartholomew J. Tortella, Jeannett Dimsits, Bertil Bouillon
Where is Hemophilia Treatment and Research research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Hemophilia Treatment and Research is open access?
ScholarIQopen access share
67%OPEN ACCESS